4 a, c) suggest that there is little to be gained by individualizing the treatment in Stage 2 since everyone benefits from the standard treatment, but at Stage 1 there may be significant clinical value in choosing treatment in a personalized fashion to maximize the overall DFS time.
← all excerpts
Dynamic Treatment Regimes Using Bayesian Additive Regression Trees for Censored Outcomes.
1
—
—